Failure of EGFR TKI treatment: mechanisms and current strategies?

Rafael Rosell (Badalona, Spain)

Source: ERS Research Seminar

Number: 6

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Rafael Rosell (Badalona, Spain). Failure of EGFR TKI treatment: mechanisms and current strategies?. ERS Research Seminar

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014
EGFR-inhibition: resistance mechanisms and new strategies Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014
Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016
Understanding the mechanisms of TKIs: the cycle of inhibition and resistance Source: International Congress 2016 – The future of tyrosin kinase inhibitors Year: 2016
Therapeutic strategy for EGFR driven NSCLC Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
EGFR TKI in the current clinical practice Source: ERS Research Seminar Year: 2015
TKIs: a new class of drugs in the management of lung cancer Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011
Re-purposing TKI treatment Source: International Congress 2016 – The future of tyrosin kinase inhibitors Year: 2016
Targeting targeted therapies: more choices and the best sequences Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005
Treatment of COPD: from pharmacological to instrumental therapies Source: Eur Respir Rev 2009; 19: 7-23 Year: 2010
Therapeutic strategies: what treatment for what patient Source: Annual Congress 2008 - PG12 - Challenges in pulmonary embolism: hot issues and interactive cases (jointly organised with ACCP) Year: 2008
Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020
Pharmacological options for the treatment of COPD: present and future Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy Year: 2007
TB following targeted and biological therapy: can we predict it? Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017